Cracking the Genomic Code of CDK4/6 Inhibitor Resistance
Seth A Wander1, Aditya Bardia2
1Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
Summary
Hormone receptor-positive metastatic breast cancer (HR+/HER2- MBC) treatment is advancing with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). Research now focuses on understanding resistance mechanisms to improve future therapies.
Area of Science:
- Oncology
- Translational Breast Cancer Research
Background:
- Metastatic hormone receptor-positive, human epidermal growth factor-2-negative breast cancer (HR+/HER2- MBC) treatment has seen significant advancements.
- Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are now standard first-line therapy, used with antiestrogens.
Purpose of the Study:
- To explore the evolving therapeutic landscape for HR+/HER2- MBC.
- To investigate the genomic and molecular mechanisms underlying resistance to current therapies, including antiestrogens and CDK4/6 inhibitors.
Main Methods:
- Review of current clinical and research literature on HR+/HER2- MBC treatment.
- Analysis of emerging therapeutic agents and resistance pathways.
Main Results:
- CDK4/6 inhibitors represent a major therapeutic advance in HR+/HER2- MBC.
- Novel antiestrogens, signal transduction inhibitors, and next-generation CDK inhibitors are under development.
- Understanding resistance mechanisms is critical for future treatment strategies.
Conclusions:
- The treatment of HR+/HER2- MBC is dynamic, with ongoing development of new therapies.
- Identifying and overcoming resistance to CDK4/6 inhibitors and antiestrogens is a key research priority.
More Related Videos
Related Concept Videos
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
7.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.4K
02:15M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:23Negative Regulator Molecules
35.4K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.4K